biostudies-literature00520Unknown15Caproni S<h4>Background</h4>The management of Medication overuse headache (MOH) represents a difficult challenge for clinicians and headache experts, particularly for the responder rate after a successful withdrawal treatment. The purpose of this study was to investigate the role of demographic and clinical characteristics as well as the score of Migraine-Specific Quality of Life Questionnaire (MSQ), Migraine Disability Questionnaire and Leeds Dependence Questionnaire in predicting a response after a successful withdrawal treatment in patients with MOH.<h4>Methods</h4>This ancillary study is part of a randomized trial that demonstrated the safety and the efficacy of a 3-month treatment with sodium valproate (VPA) (800 mg/day vs placebo) in MOH. Demographic and clinical characteristics and questionnaire results were obtained from the entire sample.<h4>Results</h4>A significant correlation was found only between MOH relapse and the total MSQ score, the Role Preventive sub-scale and the Emotional Function sub-scale, suggesting a poorer quality of life in non responders.<h4>Conclusion</h4>A high MSQ score could be associated with a poor short-term outcome in MOH patients after a successful treatment with detoxification followed by a new treatment.BMC neurology85https://www.ebi.ac.uk/biostudies/studies/S-EPMC4460700biostudies-literatureMigraine-specific quality of life questionnaire and relapse of medication overuse headache.PMC4460700Caproni SBianchi ESAMOHA Study GroupCorbelli ISarchielli PCalabresi PBeghi ECupini LM52falseMigraine-specific quality of life questionnaire and relapse of medication overuse headache.<h4>Background</h4>The management of Medication overuse headache (MOH) represents a difficult challenge for clinicians and headache experts, particularly for the responder rate after a successful withdrawal treatment. The purpose of this study was to investigate the role of demographic and clinical characteristics as well as the score of Migraine-Specific Quality of Life Questionnaire (MSQ), Migraine Disability Questionnaire and Leeds Dependence Questionnaire in predicting a response after a successful withdrawal treatment in patients with MOH.<h4>Methods</h4>This ancillary study is part of a randomized trial that demonstrated the safety and the efficacy of a 3-month treatment with sodium valproate (VPA) (800 mg/day vs placebo) in MOH. Demographic and clinical characteristics and questionnaire results were obtained from the entire sample.<h4>Results</h4>A significant correlation was found only between MOH relapse and the total MSQ score, the Role Preventive sub-scale and the Emotional Function sub-scale, suggesting a poorer quality of life in non responders.<h4>Conclusion</h4>A high MSQ score could be associated with a poor short-term outcome in MOH patients after a successful treatment with detoxification followed by a new treatment.2015-01-01T00:00:00Z2015 May2024-11-12T06:54:54.039Z2019-03-27T01:53:08ZS-EPMC44607002599100810.1186/s12883-015-0339-8